

Streamline
Health[®]

First Quarter 2021 Earnings Presentation

Nasdaq: STRM



Disclosure Statement

SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE

This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health’s actual results to differ. We caution you therefore to not place undue reliance on such statements.

Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health’s periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.


TRADEMARKS

Product or company names referenced herein may be trademarks or registered trademarks of their respective owners

First Quarter 2021 Highlights

Transforming hospital mid-revenue cycle management

SaaS Revenue



32% Growth of SaaS revenue in 1Q21 vs 1Q20.
Driven by significant eValuator growth

\$16.7M

Cash & Cash Equivalents
as of 4/30/21

Clean balance sheet and cap table with no debt other than PPP loan

\$2.6M

Total new bookings during 1Q21

Sales Update

- Pipeline continues to grow: **TCV ↑ 20%**
- Investing in **salesforce expansion**, new RVP's & Business Development Representatives
- Continuing **reseller expansion**, adding large RCM services providers
- Customer success team building stable of **referenceable clients**
- Maintaining **\$2-\$3M quarterly bookings goal**

Financial Results

Income Statement

	Three Months Ended April 30, 2021	Three Months Ended April 30, 2020
Revenue	\$3.0M	\$2.8M
Operating Expenses	\$5.4M	\$4.4M
Loss From Continuing Operations	(\$2.5M)	(\$1.0M)
Net Income/(Loss)	(\$2.1M)	\$3.7M
Adj. EBITDA*	(\$0.7M)	(\$0.6M)




*Streamline Health defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees.


Financial Results

Balance Sheet

	As of April 30, 2021	As of January 31, 2021
Cash & Cash Equivalents	\$16.7M	\$2.4M
Total Current Assets	\$21.6M	\$7.3M
Total Current Liabilities	\$9.1M	\$7.4M
Total Bank Debt Outstanding	\$0.0M	\$0.0M

Looking Forward

-  Focused on persistent, sequential revenue growth
-  Project continued growth of recurring SaaS revenue as a percentage of total revenue
-  Anticipating cash from operations breakeven during 2Q or 3Q 2022



Streamline
Health[®]

First Quarter 2021 Earnings Presentation
Nasdaq: STRM

